Predictors and Implications of Stent Thrombosis in Non–ST-Segment Elevation Acute Coronary Syndromes
- 1 December 2011
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation: Cardiovascular Interventions
- Vol. 4 (6), 577-584
- https://doi.org/10.1161/circinterventions.111.963884
Abstract
Background—: The frequency, predictors, and consequences of stent thrombosis (ST) in patients with non–ST-segment elevation acute coronary syndromes (NSTE-ACS) have been incompletely studied. We sought to investigate the incidence, predictors, and clinical implications of ST occurring within 1 year after percutaneous coronary intervention in patients with NSTE-ACS. Methods and Results—: The Acute Catheterization and Urgent Intervention Triage StrategY (ACUITY) trial was a large-scale, prospective, randomized trial of antithrombotic regimens in patients with NSTE-ACS. The present analysis includes 7162 patients in whom stents were implanted. At 1 year, definite/probable ST occurred in 146 patients (2.2%), including 94 definite and 52 probable events. There were 100 episodes (1.4%) of early ST (within the first 30 days) and 46 episodes (0.8%) of late ST (between 30 days and 1 year). The incidence of ST within 1 year was similar in patients treated with drug-eluting stents or bare metal stents (hazard ratio, 0.86; 95% confidence interval, 0.62–1.20; P =0.38) and was independent of procedural antithrombotic treatment. Patients with ST compared with those without ST had strikingly higher 1-year rates of cardiac mortality (32.4% versus 2.9%, P P P <0.0001). Independent predictors of 1-year definite/probable ST were insulin-treated diabetes mellitus, number of diseased vessels, and ST-segment deviation ≥1 mm. Conclusions—: Compared with elective stent implantation, ST occurs with increased frequency in the first year after stent implantation in patients with NSTE-ACS, especially within the first 30 days, and is associated with marked increases in cardiac mortality and adverse events. Insulin-treated diabetes, number of diseased vessels, and dynamic ST-segment changes were independent predictors of 1-year ST in NSTE-ACS. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT00093158.Keywords
This publication has 32 references indexed in Scilit:
- The Pathology of Neoatherosclerosis in Human Coronary ImplantsJournal of the American College of Cardiology, 2011
- The Risk of Stent Thrombosis in Patients With Acute Coronary Syndromes Treated With Bare-Metal and Drug-Eluting StentsJACC: Cardiovascular Interventions, 2009
- A Volumetric Intravascular Ultrasound Comparison of Early Drug-Eluting Stent Thrombosis Versus RestenosisJACC: Cardiovascular Interventions, 2009
- Early Stent Thrombosis in Patients With Acute Coronary Syndromes Treated With Drug-Eluting and Bare Metal StentsCirculation, 2009
- Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trialThe Lancet, 2009
- Prasugrel versus Clopidogrel in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 2007
- Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: Study design and rationaleAmerican Heart Journal, 2004
- Impact of coronary artery stents on mortality and nonfatal myocardial infarction: meta-analysis of randomized trials comparing a strategy of routine stenting with that of balloon angioplastyAmerican Heart Journal, 2004
- Activation of the inflammation, coagulation, and fibrinolysis systems, without influence of abciximab infusion in patients with non-ST–elevation acute coronary syndromes treated with dalteparin: a GUSTO IV substudyAmerican Heart Journal, 2004
- Clopidogrel for Coronary StentingCirculation, 2003